Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Part of paid clinical trials in St Louis, Missouri.
- Sponsor
- Washington University School of Medicine
- Study ID
- NCT04887935
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Cancer of Prostate
- Prostate Cancer
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin — DRUG-The 10 mg dose is reflective of current clinical practice for diabetes and heart failure
Study Details
This is a pilot study of the tolerability and safety of neoadjuvant dapagliflozin for patients with unfavorable intermediate, high-risk, or very high-risk prostatic adenocarcinoma prior to radical prostatectomy. The primary hypothesis is that four weeks of daily dapagliflozin prior to surgery is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious in resulting in tumor shrinkage on pre-operative imaging and will result in tumor necrosis at prostatectomy.
Key Dates
- Start date
- Jun 4, 2024
- Status verified
- Sep 2025
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Dapagliflozin* Dapagliflozin will be initiated once daily approximately 6 weeks prior to planned prostatectomy * Dapagliflozin will be given at 10 mg by mouth once daily for 4 weeks (days 1-28) prior to prostatectomy.
Primary Outcome Measure
Frequency and severity of toxicities related to dapagliflozin as measured by CTCAE v 5.0 [ Time Frame: From cycle 1 day 1 (the cycle is 28 days in length) through 30 days after prostatectomy (approximately day 64) ]
Central Contacts
- Melissa A Reimers, M.D.314-362-5740
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | Melissa A Reimers, M.D. (PRINCIPAL_INVESTIGATOR) Linda R Peterson, M.D. (SUB_INVESTIGATOR) Joseph E Ippolito, M.D., Ph.D. (SUB_INVESTIGATOR) Woodson W Smelser, M.D. (SUB_INVESTIGATOR) Janet McGill, M.D. (SUB_INVESTIGATOR) Jingqin (Rosy) Luo, Ph.D. (SUB_INVESTIGATOR) |
Find similar trials in St Louis, MO
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyPHASE2 · Recruiting · Astellas Pharma Global Development, Inc. · Anchorage, Alaska
- Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate BrachytherapyPHASE1/PHASE2 · Recruiting · Washington University School of Medicine · St Louis, Missouri
- Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical ProstatectomyPHASE2 · Recruiting · David Oh · San Francisco, California